
<DOC>
<DOCNO>WT02-B24-139</DOCNO>
<DOCOLDNO>IA089-000954-B013-372</DOCOLDNO>
<DOCHDR>
http://www.ldanatl.org:80/articles/seab/weinberg/table12.html 206.86.190.251 19970109190103 text/html 5831
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 19:01:06 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 5649
Last-modified: Fri, 11 Oct 1996 05:39:26 GMT
</DOCHDR>
<html>
<head>
<title>Table 12. Antimanic Pharmacotherapy</title>
</head>
<body bgcolor="#FFFFFF">
<h1 align=center> Table 12. Antimanic Pharmacotherapy</h1>

<table border=1>
<tr><td valign=top rowspan=15><b>Lithium carbonate</b></td>
    <td rowspan=2 valign=top>Dosage Range</td>
    <td>Children 20-40 mg/kg/d<br>
        (600-1200 mg/d)</td>
<tr><td>Adolescents 600-1800 mg/d<br>
        (use tid dosage schedule for<br>
        regular tablets and bid schedule<br>
        for sustained-release tablets)</td></tr>
<tr><td>Serum level</td>
    <td>0.8-1.4 mEq/L</td></tr>
<tr><td valign=top>Indications</td>
    <td>Drug of choice in manic-depressive disease when other
        conventional regiments for depressive and manic 
        symptomatology fail, often used in
        combination with an antidepressant</td></tr>
<tr><td valign=top rowspan=2>Contraindications</td>
    <td>Renal disease</td></tr>
<tr><td>Unrecognized thyroid disease </tr></td>
<tr><td valign=top rowspan=9>Potential Adverse Effects</td>
    <td>Induction or promotion of depression</td></tr>
<tr><td>Tremor</td></tr>
<tr><td>Increased appetite and excess weight gain </td></tr>
<tr><td>Excessive daytime sleepiness</td></tr>
<tr><td>Polydipsia and polyuria with  resultant hyponatremia </td></tr>
<tr><td>Hypothyroidism; nontoxic goiter</td></tr>
<tr><td>Parathyroid dysfunction</td></tr>
<tr><td>EEG spike discharges+</td></tr>
<tr><td>EKG conduction changes+</td></tr>


<tr><td valign=top rowspan=13><b>Thioridazine</b></td> 
    <td rowspan=2 valign=top>Dosage Range</td>
    <td>Children 10-15 mg<br>bid, tid, or qid</td></tr>
<tr><td>Adolescents 10-25 mg<br>bid, tid or qid</td></tr>
<tr><td>Serum level</td>
    <td>Not available</td></tr>
<tr><td valign=top>Indications</td>
    <td>Primary drug of choice for minor manic states and 
        as an additional drug for manic states induced or 
        promoted by antidepressant drugs </td></tr>
<tr><td valign=top rowspan=3>Contraindications</td>
    <td>Obesity</td></tr>
<tr><td>Hepatic disease</td></tr>
<tr><td>Excessive daytime sleepiness </td></tr>
<tr><td valign=top rowspan=6>Potential Adverse Effects</td>
     <td>Induction or promotion of depression 
<tr><td>Increased appetite and excess weight gain </td></tr>
<tr><td>Excessive daytime sleepiness</td></tr>
<tr><td>Rash</td></tr>
<tr><td>Dyskinesias</td></tr>
<tr><td>Retinitis</td></tr>


<tr><td valign=top rowspan=15><b>Carbamazepine</b></td>
    <td rowspan=2 valign=top>Dosage Range</td>
    <td>Children 10-20 mg/kg/d</td></tr>
<tr><td>Adolescents 200-1200  mg/d<br>
        (use bid or tid  dosage schedule)</td></tr>
<tr><td>Serum level</td>
    <td>4-12 g/ml</td></tr>
<tr><td valign=top rowspan=2>Indications</td>
    <td>Primary drug of choice for manic rages if relatively 
        free of  depression; excessive daytime sleepiness, 
        and petit mal epilepsy</td></tr> 
<tr><td>May be added to other drug 
        regimes to control manic 
        rages</td></tr>
<tr><td valign=top rowspan=5>Contraindications</td>
    <td>Excessive daytime sleepiness</td></tr>
<tr><td>Depressive irritability and anger</td></tr> 
<tr><td>Petit mal epilepsy</td></tr>
<tr><td>Hepatic disease</td></tr>
<tr><td>Blood dyscrasia</td></tr>
<tr><td valign=top rowspan=5>Potential Adverse Effects</td>
    <td>Excessive daytime sleepiness </td></tr>
<tr><td>Inducion or promotion of depression </td></tr>
<tr><td>Hepatoxicity </td></tr>
<tr><td>Hematologic abnormalities </td></tr>
<tr><td>Rash</td></tr>


<tr><td valign=top rowspan=11><b>Methylphenidate</b></td> 
    <td valign=top>Dosage Range</td>
    <td>10-60 mg/d (bid or tid dosages*)</td></tr>
<tr><td>Serum level</td>
    <td>Not available</td></tr>
<tr><td valign=top rowspan=2>Indications</td>
    <td>Primary drug of choice for chronic hypomania and for 
        excessive daytime sleepiness (hypovigilance)</td></tr> 
<tr><td>May be added to antidepressant drug regimen in rapidly 
        cycling  manic-depressive disease (or cyclothymia)</td></tr>
<tr><td valign=top rowspan=3>Contraindications</td>
     <td>Depressive symptomatology</td></tr>
<tr><td>Hypertension</td></tr>
<tr><td>Chronic tic syndrome</tr></td>
<tr><td valign=top rowspan=4>Potential Adverse Effects</td>
    <td>Hypertension </tr></td>
<tr><td>Induction or promotion of depressive symptomatology 
        particularly vegetative symptoms (anorexia, weight loss 
        insomnia, somatic complaints) </tr></td> 
<tr><td>Transient growth retardation </tr></td>
<tr><td>Tics</tr></td>


<tr><td valign=top rowspan=5><b>Pemoline</b></td> 
    <td valign=top>Dosage Range</td>
    <td>37.5-112.5 mg/d in bid or tid dosages)</td></tr>

<tr><td>Serum level</td>
    <td>Not available</td></tr>
<tr><td valign=top>Indications</td>
    <td>Secondary drug for chronic hypomanic and for 
        excessive daytime sleepiness</td></tr>

<tr><td valign=top>Contraindications</td>
    <td>Same as methylphenidate</td></td>

<tr><td valign=top>Potential Adverse Effects</td>
    <td>Same as methylphenidate, plus  elevation of liver 
        enzymes</td></tr> 

</table>
<p>* Last dose should not be given after 4 pm<br>
+ EKG = electrocardiogram<br>
+ EEG = electroencephalogram <br>
<p>From Brumback RA, Weinberg WA: Pediatric behavioral neurology:An
update on the neurologic aspects of depression, hyperactivity, and
learning disabilities. <i>Neurol Clin</i> 8:677-703, 1990 and adapted
from Levy HB, Harper CR, Weinberg WA: A practical 
approach to children failing in school. <i>Pediatr Clin North Am</i>
39:895-928, l992 

<p align=center>Back to <a href="">Depression & Other Affective
Illnesses</a>

</body>
</html>
</DOC>